<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0027873" disease_type="Disease or Syndrome" abbrv="">Neuromyelitis optica</z:e> (<z:chebi fb="0" ids="52093">NMO</z:chebi>) is a <z:e sem="disease" ids="C0011303" disease_type="Disease or Syndrome" abbrv="">demyelinating disease</z:e> of the central <z:mp ids='MP_0008912'>nervous</z:mp> system characterized by severe episodes of optic nerve and spinal cord <z:mp ids='MP_0001845'>inflammation</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="52093">NMO</z:chebi>-IgG (anti-aquaporin-4) has been recently described as a sensitive and specific marker for <z:chebi fb="0" ids="52093">NMO</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>As there have been prior published reports of an association between <z:chebi fb="0" ids="52093">NMO</z:chebi> and systemic <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo>, the prognostic value of the antibody test in these cases is uncertain </plain></SENT>
<SENT sid="3" pm="."><plain>We describe a 47-year old woman with recurrent <z:e sem="disease" ids="C0026976" disease_type="Disease or Syndrome" abbrv="">transverse myelitis</z:e> and a long-standing history of <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE) and <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> syndrome (APLS) </plain></SENT>
<SENT sid="4" pm="."><plain>While she did not have a history of <z:hpo ids='HP_0100653'>optic neuritis</z:hpo>, serological testing for the <z:chebi fb="0" ids="52093">NMO</z:chebi>-IgG was positive when she was admitted for her second episode of <z:e sem="disease" ids="C0026976" disease_type="Disease or Syndrome" abbrv="">transverse myelitis</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Testing for the <z:chebi fb="0" ids="52093">NMO</z:chebi>-IgG in cases of isolated or recurrent <z:e sem="disease" ids="C0026976" disease_type="Disease or Syndrome" abbrv="">transverse myelitis</z:e> attributed to current SLE and APLS may help clarify the diagnosis of a distinct disease process likely to cause recurrent and severe disability, warranting more aggressive immunotherapy </plain></SENT>
</text></document>